中國先鋒醫藥(01345.HK)公佈年度業績 純利增加173.5%至1.41億元 毛利率增加至53.8%
格隆匯3月31日丨中國先鋒醫藥(01345.HK)公佈，截至2021年12月31日止年度，公司收益增加7.7%至人民幣14.35億元，毛利增加27.0%至人民幣7.72億元，期間純利增加173.5%至人民幣1.41億元，每股基本盈利人民幣0.12元，末期股息每股0.064港元。
集團平均毛利率由2020年的45.6%增加至2021年的53.8%。集團通過提供綜合性營銷、推廣及管道管理服務銷售的藥品的毛利率由2020年的66.0%增加至2021年的66.3%，與去年同期相比，報吿期的毛利率保持相對穩定。集團通過提供綜合性營銷、推廣及管道管理服務銷售的醫療器械的毛利率由2020年的44.6%增加至2021年的53.5%，主要由於公司大幅提升了毛利率較高產品的銷售比重。集團通過聯合推廣及管道管理服務銷售的產品毛利率由2020年的2.9%增加至2021年的7.8%。
報吿期內，集團通過提供綜合性營銷、推廣及管道管理服務的藥品收益為人民幣991.1百萬元，較去年增加21.5%，佔本集團於報吿期內收益69.1%。毛利為人民幣656.6百萬元，較去年增加22.0%，佔集團於報吿期內毛利85.1%。
報吿期內，集團通過提供綜合性營銷、推廣及管道管理服務的醫療器械收益為人民幣187.2百萬元，較去年增加12.8%，佔本集團於報吿期內收益13.0%。毛利為人民幣100.2百萬元，較去年增加35.4%，佔集團於報吿期內毛利13.0%。
集團藥品業務板塊其他產品也擺脱了新冠疫情所帶來的的不利影響，相較過去一年保持了良好的發展態勢。報吿期內，集團這些產品實現的收益為人民幣235.4百萬元，較去年同期增加39.9%。
報吿期內，集團營銷網絡的發展帶來市場覆蓋的明顯提升。比如戴芬新增覆蓋醫院和醫療機構2,787家，而希弗全新增覆蓋醫院704家。隨着醫藥市場環境的不斷變化，更為完善和健康的營銷網絡，是集團運營的重要基礎。
集團將繼續圍繞產品開發引進、深度挖掘產品營銷及推廣能力、合作共贏擴大產品市場覆蓋、適時通過併購方式充實產業鏈這幾方面，在中國醫藥行業格局的變化中積極應對，鋭意進取，實現未來發展的新藍圖。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
